CN109415361A - 丙烯酸类衍生物及其制备方法和其在医药上的用途 - Google Patents

丙烯酸类衍生物及其制备方法和其在医药上的用途 Download PDF

Info

Publication number
CN109415361A
CN109415361A CN201780038512.9A CN201780038512A CN109415361A CN 109415361 A CN109415361 A CN 109415361A CN 201780038512 A CN201780038512 A CN 201780038512A CN 109415361 A CN109415361 A CN 109415361A
Authority
CN
China
Prior art keywords
alkyl
compound
fluoro
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780038512.9A
Other languages
English (en)
Other versions
CN109415361B (zh
Inventor
关东亮
盛首
盛首一
白骅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Hisun Pharmaceutical Co Ltd
Shanghai Aryl Pharmtech Co Ltd
Original Assignee
Zhejiang Hisun Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharmaceutical Co Ltd filed Critical Zhejiang Hisun Pharmaceutical Co Ltd
Publication of CN109415361A publication Critical patent/CN109415361A/zh
Application granted granted Critical
Publication of CN109415361B publication Critical patent/CN109415361B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种通式(I)所示的丙烯酸类衍生物、其立体异构体、互变异构体或其可药用的盐，它们的制备方法，含有它们的药物组合物，以及它们作为治疗剂，特别是作为选择性雌激素受体下调剂(SERD)的用途，其中通式(I)中的R1、R2、R3、R4的定义如说明书所述。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201780038512.9A 2016-06-29 2017-06-27 丙烯酸类衍生物及其制备方法和其在医药上的用途 Active CN109415361B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610524780 2016-06-29
CN2016105247809 2016-06-29
PCT/CN2017/090253 WO2018001232A1 (zh) 2016-06-29 2017-06-27 丙烯酸类衍生物及其制备方法和其在医药上的用途

Publications (2)

Publication Number Publication Date
CN109415361A true CN109415361A (zh) 2019-03-01
CN109415361B CN109415361B (zh) 2022-03-08

Family

ID=60785936

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780038512.9A Active CN109415361B (zh) 2016-06-29 2017-06-27 丙烯酸类衍生物及其制备方法和其在医药上的用途

Country Status (3)

Country Link
CN (1) CN109415361B (zh)
TW (1) TWI651321B (zh)
WO (1) WO2018001232A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108329311A (zh) * 2017-01-11 2018-07-27 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3017388C (en) 2016-04-01 2024-03-12 Zeno Royalties & Milestones, LLC Estrogen receptor modulators
US10125135B2 (en) 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
WO2018019793A1 (en) 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
US10131663B2 (en) 2016-10-24 2018-11-20 Astrazeneca Ab Chemical compounds
DK3494116T3 (da) 2017-01-30 2020-01-27 Astrazeneca Østrogenreceptormodulatorer
GB2577315A (en) * 2018-09-21 2020-03-25 Mexichem Fluor Sa De Cv Methods
EP3993787A4 (en) 2019-08-06 2023-07-12 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF MUTANTS
AU2021269612A1 (en) * 2020-05-15 2023-01-05 Jiangsu Simcere Pharmaceutical Co., Ltd. Pyrrolidine compound and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105229004A (zh) * 2013-05-28 2016-01-06 阿斯利康(瑞典)有限公司 化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107428758B (zh) * 2015-11-12 2020-08-04 浙江海正药业股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105229004A (zh) * 2013-05-28 2016-01-06 阿斯利康(瑞典)有限公司 化合物
US20160136140A1 (en) * 2013-05-28 2016-05-19 Astrazeneca Ab Chemical Compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108329311A (zh) * 2017-01-11 2018-07-27 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
CN108329311B (zh) * 2017-01-11 2022-02-22 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用

Also Published As

Publication number Publication date
WO2018001232A1 (zh) 2018-01-04
CN109415361B (zh) 2022-03-08
TWI651321B (zh) 2019-02-21
TW201808951A (zh) 2018-03-16

Similar Documents

Publication Publication Date Title
CN109415361A (zh) 丙烯酸类衍生物及其制备方法和其在医药上的用途
CN107428758A (zh) 丙烯酸类衍生物、其制备方法及其在医药上的用途
Zhang et al. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)
EP1678166B1 (en) Protein kinase inhibitors
JP5492565B2 (ja) Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
KR101483215B1 (ko) 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
TWI662026B (zh) 吡啶酮類衍生物、其製備方法及其在醫藥上的應用
CN103930425B (zh) 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
JP6192708B2 (ja) Ｃ−ｍｅｔプロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−イミダゾ［４，５−ｂ］ピリジン化合物および３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
EP3556761B1 (en) Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof
EP2985283B1 (en) Anti-angiogenesis compound, intermediate and use thereof
JP2021536436A (ja) キノリン誘導体から調製される新規な阻害剤
CN105968115A (zh) 喹啉类化合物、其制备方法、中间体、药物组合物和应用
JP2022549601A (ja) ヘテロアリール血漿カリクレインインヒビター
WO2019223766A1 (zh) 一种fgfr抑制剂、其制备方法和在药学上的应用
CN114181208B (zh) 三并环类AhR抑制剂及其用途
TW202028195A (zh) 作為TGF-βR1抑制劑的化合物及其應用
RU2472792C2 (ru) Соединения 2-(2-оксоиндолин-3-илиден)метил-5-(2-гидрокси-3-морфолин-4-илпропил)-6,7 дигидро-1-н-пиррол[3,2-с]пиридин-4(5н)-она и их применение в качестве ингибиторов протеинкиназы
CN108264511B (zh) 杂环类衍生物及其制备方法和其在医药上的用途
TW200524937A (en) Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands
WO2020052349A1 (zh) Fgfr抑制剂、其制备方法和应用
WO2016041201A1 (zh) 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
CN105473590A (zh) 用于治疗增殖性障碍的1h-吡唑并[3,4-b]吡啶衍生物及其药物组合物
WO2018205938A1 (zh) Parp抑制剂、其药物组合物、制备方法和应用
CN114502556B (zh) 一种联苯基氟代双键衍生物及其制备方法和在药学上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220518

Address after: Jiaojiang District of Taizhou City, Zhejiang province 318000 road outside No. 46

Patentee after: ZHEJIANG HISUN PHARMACEUTICAL Co.,Ltd.

Patentee after: Shanghai Angrui Pharmaceutical Technology Co., Ltd

Address before: Jiaojiang District of Taizhou City, Zhejiang province 318000 road outside No. 46

Patentee before: ZHEJIANG HISUN PHARMACEUTICAL Co.,Ltd.